Designer baby companies are in turmoil

Two companies that It was launched last year with plans to create… Genetically modified children It has already closed, due to financial problems and internal strife.

One of them, Manhattan Genomics in New York, suddenly closed its doors soon after advertisement A team of scientific advisors in October, including a leading fertility doctor and a data scientist from De-Extinction Company. Phenomenal biological scienceAnd a pioneering scientist, A Three-parent artificial insemination. technique. The other company, California-based Bootstrap Bio, said it would cease operations in late 2025, for the first time. I mentioned By Mother Jones.

Manhattan Genomics and Bootstrap Bio had ambitions to edit DNA in human embryos with the goal of preventing serious diseases in children. This idea, known as germline editing, is highly controversial because any changes made at the fetal level will be passed on to future generations. It’s different from Gene editing therapies It is currently being tested on patients, which only affects the individual being treated.

The safety and effectiveness of germline editing are also important Not installed. One concern is that this technology could lead to unintended, and potentially harmful, “off-target” modifications. Many researchers worry that allowing embryos to be edited to treat serious diseases will inevitably lead to them being used for enhancement purposes, such as appearance or intelligence, to produce “designer babies.” It is currently prohibited in the United States and many other countries to start a pregnancy with an altered embryo.

There are three known children whose genes were modified as embryos as part of an infamous experiment in 2018 conducted by a Chinese scientist. He Jiankui. This revelation shocked the international scientific community, and a Chinese court sentenced He to three years in prison on charges of illegal medical practices. Once taboo, the idea of ​​creating genetically modified children has recently been revived by biotech entrepreneurs, futurists, and investors in Silicon Valley. But the path to a viable project to create newborns using gene editing appears to present some challenges.

“We ran out of money,” Chase Denke, CEO and co-founder of Bootstrap Bio, told WIRED via email. “We had some promising results in the lab, but I couldn’t get enough investors interested in us to continue our operations.” He added that the company still exists but is not actively operating.

Bootstrap had other problems. In August 2025, federal officers Arrested The company’s chief science officer at the time, Zhichen Yuan, was charged with attempted child sex trafficking, Mother Jones reported. Yuan is now scheduled to appear in federal court in Boston. When reached by email, Yuan’s lawyer declined to comment.

Deneke told WIRED he was not aware of the charges until after the company “ceased active operations.” Yuan worked as a contractor for Bootstrap Bio in 2024 and 2025 until the company closed, according to Deneke. “We would have let him leave early if we had known,” Deneke said via email.

Bootstrap Bio has received early interest from investors. In a LinkedIn 2024 post For example, when announcing the startup, Deneke mentioned that a venture capitalist had flown him to Honduras.

Manhattan Genomics, which also oversaw the Manhattan Project, planned to pursue editing human embryos to prevent disease. In a Since X’s post was deleted As of March, co-founder Cathy Tai said the startup had shut down due to a “conflict between the founders.” And at the same time publicly Announce Forming a new company, Origin Genomics, to advance germline gene correction.

Manhattan Genomics co-founder Ireona Hesoli told WIRED that she and Tai parted ways due to “fundamental differences arising from the coexistence of a Cayman-based entity of the same name with separate management by the co-founder, which confounded the open and transparent mission of Manhattan Genomics.”